MERZ AESTHETICS AND NEOCUTIS TO CONTRIBUTE TO "LOOK GOOD FEEL BETTER" THIS HOLIDAY SEASON

Merz North America
Mariana Smith
Corporate Communications
4215 Tudor Lane
Greensboro, NC 27410
Office (336) 217-2636
Cell (615) 631-6795
msmith@merzusa.com

www.merzusa.com

GREENSBORO, N.C. – BUSINESS WIRE – Merz North America today announced that Merz Aesthetics, a division of Merz North America, and **NEO**CUTIS will contribute a portion of their product sales in the month of December to benefit **Look Good Feel Better®**, a charitable organization, that for more than 24 years, has worked to give confidence to women undergoing treatment for cancer.

"The Look Good Feel Better program's mission aligns with the philosophy we have at Merz Aesthetics," said Jim Hartman, Vice President and Head of U.S. Aesthetics/ OTC at Merz North America. "Our focus is not just on helping women and men look their best, but contributing to how they feel both inside and out. We are thankful for the opportunity to contribute to a mission we so strongly support."

"We are always grateful for the contributions made by organizations like Merz Aesthetics and **NEO**CUTIS," said Louanne Roark, executive director of the Personal Care Products Council Foundation and the Look Good Feel Better program. "Contributions to Look Good Feel Better allow the program to give the hundreds of thousands of women diagnosed with cancer every year back control, confidence and hope during a difficult time."

"**NEO**CUTIS is happy to partner with our new colleagues at Merz North America in contributing to this incredible organization," Mark Lemko, Head of NEOCUTIS, Inc. said. "We look forward to expanded philanthropic partnerships in the future."

The amount of the Merz Aesthetics and **NEO**CUTIS contributions will be based on a portion of sales of aesthetic products sold directly to physicians from December 1, 2013 through December 31, 2013. Sales of the following products are considered to determine the contribution: Radiesse® Volumizing Filler, Belotero Balance®, Xeomin® (incobotulinumtoxinA), the **NEO**CUTIS family of products, the Mederma® family of products for scar care and stretch marks, and Merz Aesthetics' injectable product for the treatment of varicose veins.

About Look Good Feel Better

Look Good Feel Better is a non-medical, brand-neutral public service program that teaches beauty techniques to cancer patients to help them manage the appearance-related side effects of cancer treatment.

Look Good Feel Better group programs are open to all women with cancer who are undergoing chemotherapy, radiation, or other forms of treatment. In the United States alone, more than 850,000 women have participated in the program,

which now offers 15,400 group workshops nationwide in more than 2,500 locations.

Thousands of volunteer beauty professionals support Look Good Feel Better. All are trained and certified by the Personal Care Products Council Foundation, the American Cancer Society, and the Professional Beauty Association at local, statewide, and national workshops. Other volunteer health care professionals and individuals also give their time to the program.

About Merz North America

Merz North America is a specialty healthcare company that develops and commercializes innovative treatment solutions in medical and aesthetic dermatology, and neurology in the U.S. and Canada. Our ambition is to become a recognized leader in the treatment of movement disorders, and in aesthetics and dermatology. Our future is promising, and we are committed to advancing new therapeutic options and improving patients' lives. For more than 100 years, the development of Merz products has been based on our commitment to providing innovative medical approaches that earn trust of patients, physicians and partners worldwide. For more information about Merz or the Company's products, please visit www.merzusa.com.

INDICATIONS AND USAGE

XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use, is a prescription medication that is injected into facial muscles for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines) in adult patients.

XEOMIN® should be administered no more frequently than every three months.

IMPORTANT SAFETY INFORMATION for XEOMIN®, INCLUDING BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use, and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these

symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses.

Please see Full Prescribing Information, including Medication Guide for more information.

CONTRAINDICATIONS

XEOMIN® is contraindicated in patients with a known hypersensitivity to the active substance botulinum toxin type A or to any of the components in the formulation and in the presence of infection at the proposed injection site(s), as injection could lead to severe local or disseminated infection.

WARNINGS AND PRECAUTIONS

- **The potency units of XEOMIN® are not interchangeable with other preparations of botulinum toxin products. Therefore, units of biological activity of XEOMIN® cannot be compared to or converted into units of any other botulinum toxin products.**

- Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur further injection of XEOMIN® should be discontinued and appropriate medical therapy immediately instituted. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders.

- Treatment with XEOMIN® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. When distant effects occur, additional respiratory muscles may be involved Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months, which may require use of a feeding tube. Aspiration may result from severe dysphagiaThese reactions can occur within hours to weeks after injection with botulinum toxin. *[See Boxed Warning]*.

- **Cervical Dystonia**: Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia. Limiting the dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia.

- **Blepharospasm**: Injection of XEOMIN® into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation. Lower lid injections should not be repeated if diplopia occurred with previous botulinum toxin injections.

- **Glabellar Lines:** Do not exceed the recommended dosage and frequency of administration of XEOMIN®. In order to reduce the complication of ptosis the following steps should be taken:
  - Avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes.

- Corrugator injections should be placed at least 1 cm above the bony supraorbital ridge.

- Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN®.

- XEOMIN® contains albumin. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and Creutzfeldt-Jakob disease (CJD). No cases of transmission of viral diseases or CJD have ever been reported for albumin.

ADVERSE REACTIONS

Cervical Dystonia: The most commonly observed adverse reactions (incidence ≥10% of patients and twice the rate of placebo) for XEOMIN® 120 Units and XEOMIN® 240 Units, respectively, were: dysphagia (13%, 18%), neck pain (7%, 15%), muscle weakness (7%, 11%), and musculoskeletal pain (7%, 4%).

Blepharospasm: The most common adverse reactions (incidence ≥10% of patients and twice the rate of placebo) for XEOMIN® were eyelid ptosis (19%), dry mouth (16%), visual impairment (12%), diarrhea (8%), and headache (7%).

Glabellar Lines: The most common adverse reaction (incidence ≥ 2% of patients and greater than placebo) for XEOMIN® was Headache (5.4%).

DRUG INTERACTIONS

Concomitant treatment of XEOMIN® and aminoglycoside antibiotics, spectinomycin, or other agents that interfere with neuromuscular transmission (e.g., tubocurarine-like agents), or muscle relaxants, should be observed closely because the effect of XEOMIN may be potentiated.

The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

USE IN PREGNANCY

Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. XEOMIN® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

PEDIATRIC USE

The safety and effectiveness of XEOMIN® in patients less than 18 years of age have not been established.

Please see Full Prescribing Information for more information on XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use, including

complete Boxed WARNING, available at www.Xeomin.com and at www.XeominAesthetic.com.

Look Good Feel Better® is a registered trademark of The Personal Care Products Council Foundation

Contact:
Merz North America
Mariana Smith
Corporate Communications
4215 Tudor Lane
Greensboro, NC 27410
Office (336) 217-2636
msmith@merzusa.com